Viking Therapeutics, Inc. (VKTX) News

Viking Therapeutics, Inc. (VKTX)

Today's Latest Price: $7.13 USD

0.02 (0.28%)

Updated Jun 4 6:55pm

Add VKTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter VKTX News Items

VKTX News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest VKTX News From Around the Web

Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences.

Yahoo | May 27, 2020

Edited Transcript of VKTX earnings conference call or presentation 30-Apr-20 8:30pm GMT

Q1 2020 Viking Therapeutics Inc Earnings Call

Yahoo | May 21, 2020

7 Biotech Stocks Wall Street Says Will Double or More

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical dat...

Yahoo | May 19, 2020

Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

SAN DIEGO, May 12, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to its 2020 Annual Meeting of Stockholders….

PR Newswire | May 12, 2020

VKTX: Slight Delay in Enrollment in Phase 2b NASH Trial Due to Ongoing Pandemic…

By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update Slight Delay in Enrollment for VOYAGE Trial Viking Therapeutics, Inc. (NASDAQ:VKTX) is currently conducting the Phase 2b VOYAGE trial of VK2809 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH). The randomized, double blind, placebo-controlled trial is expected to enroll approximately 340

Yahoo | May 5, 2020

3 “Strong Buy” Biotech Stocks Trading Under $10

Wall Street is experiencing some major déjà vu. The tensions between the U.S. and China flared after President Trump threatened to impose new import tariffs. The difference this time? These tariffs would serve as a punishment for China’s role in the COVID-19 pandemic. In response, stocks posted sharp declines, a rough start to the month of May.The new week of trading could see more of the same. U.S. stock pointed to losses in Monday's trading session as statements made by U.S. Secretary of State Mike Pompeo the day before failed to alleviate trade war fears. Going off of the administration’s earlier statements, Pompeo supported the President’s claim that the virus originated in a Wuhan, China laboratory, adding that the country also stocked up on medical supplies while covering up the e...

Yahoo | May 4, 2020

Viking Therapeutics Inc (VKTX) Q1 2020 Earnings Call Transcript

VKTX earnings call for the period ending March 31, 2020.

Yahoo | May 1, 2020

Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

SAN DIEGO, April 30, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended…

PR Newswire | April 30, 2020

Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020

SAN DIEGO, April 23, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results…

PR Newswire | April 23, 2020

Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference

SAN DIEGO, April 7, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in the Needham &…

PR Newswire | April 7, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6356 seconds.